Iovance Biotherapeutics (IOVA) is the lead sponsor of 8 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 6 Phase 2[2], 3 Phase 1[3].
Trial NCT05727904[5] evaluates Lifileucel plus Pembrolizumab in Metastatic Melanoma with a target enrollment of 670 participants.
No Form 4 insider filings for IOVA were recorded at the SEC in the past 30 days[6].